Valuation: Bristol-Myers Squibb Company

Market Cap 118B 103B 95.79B 88.08B 166B 11,243B 170B 1,142B 447B 5,525B 441B 432B 19,096B P/E 2026 *
11.7x
P/E 2027 * 11.5x
Enterprise Value 147B 129B 120B 110B 208B 14,029B 212B 1,425B 558B 6,893B 551B 539B 23,827B EV / Sales 2026 *
3.1x
EV / Sales 2027 * 3.03x
Free-Float
69.8%
Yield 2026 *
4.23%
Yield 2027 * 4.32%
1 day+4.82%
1 week-2.04%
Current month+3.92%
1 month-0.49%
3 months-3.95%
6 months+6.86%
Current year+5.27%
1 week 56.7
Extreme 56.7
56.7
1 month 54.56
Extreme 54.56
57.88
Current year 52.02
Extreme 52.02
59.46
1 year 43.5
Extreme 43.5
59.46
3 years 40.1
Extreme 40.1
72.7
5 years 40.1
Extreme 40.1
72.7
10 years 40.1
Extreme 40.1
72.7
Manager TitleAgeSince
Chief Executive Officer 55 2023-10-31
Director of Finance/CFO 58 2019-11-19
Chief Tech/Sci/R&D Officer 53 2021-12-31
Director TitleAgeSince
Chairman 55 2024-03-31
Director/Board Member 61 2016-03-31
Director/Board Member 71 2017-02-20
Change 5-day change 1-year change 3-year change Capi.($)
+4.82%-2.04% - - 118B
-0.56%-2.64%+49.04%+168.24% 1,060B
+0.31%-2.00%+64.29%+63.06% 619B
-0.03%-5.01%+28.86%+83.73% 438B
-1.75%-2.91%+28.78%+24.35% 333B
+0.24%-2.61%+29.46%+46.50% 282B
-1.75%-12.77%+20.67%+23.05% 267B
+0.67%-0.76%-26.10%-37.25% 218B
-0.81%-3.66%+22.07%+59.72% 196B
+1.21%+0.10%+19.85%+72.03% 161B
Average +0.13%-3.33%+26.32%+55.94% 397.1B
Weighted average by Cap. +0.09%-3.10%+36.27%+82.99%

Financials

2026 *2027 *
Net sales 47.37B 41.62B 38.59B 35.49B 67.04B 4,530B 68.49B 460B 180B 2,226B 178B 174B 7,694B 46.31B 40.68B 37.72B 34.69B 65.53B 4,428B 66.95B 450B 176B 2,176B 174B 170B 7,520B
Net income 10.53B 9.25B 8.58B 7.89B 14.9B 1,007B 15.22B 102B 40.04B 495B 39.53B 38.67B 1,710B 10.26B 9.01B 8.36B 7.68B 14.52B 981B 14.83B 99.62B 39.01B 482B 38.52B 37.67B 1,666B
Net Debt 29.13B 25.59B 23.73B 21.82B 41.22B 2,785B 42.12B 283B 111B 1,369B 109B 107B 4,731B 22.67B 19.92B 18.47B 16.99B 32.09B 2,168B 32.78B 220B 86.22B 1,065B 85.13B 83.27B 3,682B
Logo Bristol-Myers Squibb Company
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 69.1% of net sales.
Employees
32,500
Date Price Change
26-07-08 US$56.70 0.00%
26-07-10 US$56.70 0.00%
26-07-09 US$56.70 0.00%
26-07-08 US$56.70 0.00%
26-07-07 US$56.70 -2.04%
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
59.34USD
Average target price
62.96USD
Spread / Average Target
+6.10%

Quarterly revenue - Rate of surprise